Concurrent Investment Advisors LLC purchased a new stake in DaVita Inc. (NYSE:DVA – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,388 shares of the company’s stock, valued at approximately $385,000.
Other large investors have also made changes to their positions in the company. Elevation Wealth Partners LLC grew its position in DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after acquiring an additional 165 shares during the period. Canada Pension Plan Investment Board purchased a new position in DaVita in the second quarter worth approximately $43,000. iSAM Funds UK Ltd purchased a new position in DaVita in the third quarter worth approximately $46,000. Stance Capital LLC purchased a new position in DaVita in the third quarter worth approximately $47,000. Finally, Smartleaf Asset Management LLC grew its position in DaVita by 34.9% in the third quarter. Smartleaf Asset Management LLC now owns 452 shares of the company’s stock worth $59,000 after acquiring an additional 117 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.
DaVita Stock Up 1.6%
NYSE:DVA opened at $154.15 on Tuesday. The stock’s fifty day moving average is $151.18 and its two-hundred day moving average is $131.51. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $159.42. The stock has a market capitalization of $10.30 billion, a price-to-earnings ratio of 15.56, a price-to-earnings-growth ratio of 0.53 and a beta of 0.84.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the company. TD Cowen reiterated a “hold” rating on shares of DaVita in a research report on Tuesday, February 3rd. UBS Group increased their price objective on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Barclays increased their price objective on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. Finally, Truist Financial set a $158.00 price objective on DaVita in a research report on Thursday, February 5th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $155.80.
Get Our Latest Analysis on DaVita
About DaVita
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Featured Articles
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
